Posted at 17:55h
by aveak
Privacy Policy Effective Date: December 24, 2018 Aptevo Therapeutics Inc. (“Aptevo” “we” or “us”) is committed to protecting the privacy of information about you. This Privacy Policy (this “Policy”) describes...
Posted at 18:54h
by aveak
...or from this website is private, confidential or secure. APTEVO THERAPEUTICS EXPRESSLY DISCLAIMS ALL REPRESENTATIONS, WARRANTIES OR CONDITIONS, EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES AND...
Posted at 15:42h
by aveak
...(CR + CRi + MLFS) BIW, twice weekly; CR, complete remission; CRi; CR with incomplete hematologic recovery; CRS, cytokine release syndrome; D, day; IDAC, intermediate dose cytarabine; IRR, infusion-related reaction;...
Posted at 01:12h
by aveak
Contact Us Aptevo Therapeutics – Headquarters 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Tel: 206-838-0500 Fax: 206-838-0503 info@apvo.com Investor Relations & Corporate Communications Miriam Weber Miller Tel: 206-859-6628 Millerm@apvo.com...
Posted at 16:21h
by aveak
...types of malignancies including, non-small cell lung, renal, pancreas, prostate, breast, colorectal, gastric, ovarian and cervical cancers. Conversely, 5T4 has limited expression on normal tissues, making it an attractive target...
Posted at 16:42h
by aveak
...Utility: Unlike chimeric antigen receptor T cell therapies (CAR-T) and bispecific CD3-based T cell engagers, APVO603 does not target a specific tumor antigen, thus allowing for broad potential therapeutic use...
Posted at 17:19h
by aveak
APVO442 (PSMA x CD3): Multi Specific Candidate for the Treatment of Prostate Cancer A Preclinical Program Utilizing ADAPTIR-FLEX to Target PSMA with High Affinity, and to CD3 with Low Affinity,...
